Eli Gilboa, PhD
The Gilboa Lab is taking multi-pronged approach to cancer immunotherapy using nucleic acid–based drug and drug delivery platforms. In this seminar, Gilboa will discuss his work on a novel vaccination concept whereby tumor cells are “marked” for vaccination by the experimental introduction of (neo)antigens. In addition, he will discuss an approach to reinvigorate exhausted HIV-specific T cells by targeting intracellular mediators of exhaustion that may be superior to PD-1 blockade with antibodies.
About the Speaker
Eli Gilboa received his PhD in molecular biology at the Weizmann Institute, Rehovot, Israel. In 2006, he joined the Sylvester Comprehensive Cancer Center and the Department of Microbiology & Immunology, Miller School of Medicine, University of Miami as the Joe Enloe Dodson Professor of Microbiology & Immunology and director of the Dodson Interdisciplinary Immunotherapy Institute. Current research in the Gilboa Lab is focused on developing a combination of complementary and synergistic cell-targeted immune stimulatory strategies using short nucleic acid based therapeutic agents.
The Center for Cell Circuitry Seminar connects investigators across disciplines to develop single-cell tools to map how cellular components connect into circuits. The center aims to develop new single-cell approaches that overcome limitations inherent in traditional techniques that analyze bulk populations of cells, thereby obscuring individual cell behavior.